In the EBV-negative DLBCL group, the high expression of KMT2D was associated with a higher IPI score (P = 0.005), and the overexpression of MYC was also related to the advanced Ann Arbor stage (P = 0.026). The gene discussed is KMT2D; the disease is diffuse large B-cell lymphoma.